Thijs Gerritzen is a curious biotechnologist currently working as Principal Scientist Process Development at Amarna Therapeutics in Leiden, The Netherlands. His work focuses on the development of a high-yielding and scalable manufacturing process for replication deficient SV40-based gene therapies. Amarna Therapeutics is a Dutch biotech company, which develops next-generation gene therapies, based on a new proprietary, non-immunogenic viral vector and production platform. Dr Gerritzen holds a PhD in BioProcess Engineering from Wageningen University in a joint project with the BioProcess Engineering group and Intravacc. During his industrial PhD project, he studied the production of bioengineered bacterial outer membrane vesicles as vaccine platform. Besides working as a scientist, Thijs is a rookie dad and likes to spend his time with his family and to explore the world with his 6-month old.